To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial Aneurysms

Exclusion Criteria

• •Patients who have contraindications to antiplatelet and/or anticoagulant therapy or do not start antiplatelet therapy in time before treatment.
• •Patients with anatomical structure is not suitable for endovascular treatment due to severe vascular tortuosity or stenosis shown by angiography.
• •Known to be allergic to Nitinol platinum alloy and angiographic agents.
• •Conditions that in the opinion of the investigators would prevent patients from completing the study, such as the expected survival period of active tumor less than 1-year, high-risk group of cerebral thrombosis, heart failure and atrial fibrillation.
• •Patients combined moyamoya disease, intracranial tumor, intracranial arteriovenous malformation, intracranial arteriovenous fistula and intracranial hematoma.
• •The target aneurysm has previously received intravascular embolization or stent implantation treatment;
• •Multiple aneurysms or complex aneurysms;
• •Patients with acute ruptured aneurysm;
• •Serious infection is not controlled and is not suitable for operation;
• •Patients who underwent major surgery or interventional therapy (such as brain, cardiac, chest, abdominal or peripheral vascular) within 30 days before surgery;
• •Obvious abnormal coagulation function or bleeding tendency;
• •Combined with severe renal insufficiency, creatinine greater than or equal to 200umol/L; Patients with severe liver diseases (such as acute and chronic hepatitis, cirrhosis), or ALT more than 3 times the upper normal limit;
• •Pregnancy, lactation, or women of childbearing age who plan to be pregnant during the study period;
• •Participation in any other clinical trial within 30 days prior to signing informed consent;
• •Other conditions considered by the investigator to be inappropriate for enrollment.